<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860702</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20150779H</org_study_id>
    <nct_id>NCT02860702</nct_id>
  </id_info>
  <brief_title>Exclusive Human Milk Feeding in Infants With Single Ventricle Physiology</brief_title>
  <official_title>A Randomized Controlled Trial to Evaluate Growth Velocity and Clinical Outcomes of Infants With Single Ventricle Physiology Fed an Exclusive Human Milk Diet With Early Nutritional Fortification Following Surgical Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prolacta Bioscience</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cook Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Childrenâ€™s Hospital of Orange County</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, blinded, controlled trial to evaluate growth velocity and clinical outcomes in
      infants with single ventricle physiology fed an exclusive human milk diet prior to, and
      throughout the post-operative period following, surgical repair. Human milk is defined as
      expressed human milk or donor milk and its derivatives, human milk-based fortifier and human
      milk caloric fortifier.

      The study hypothesis is that infants fed an exclusive human milk diet will have short and
      long term benefits, with improved wound healing, growth, and neurodevelopmental outcomes
      while reducing episodes of feeding intolerance and necrotizing enterocolitis (NEC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single blinded (physician investigator), randomized, controlled trial to evaluate
      growth velocity and clinical outcomes in infants with single ventricle physiology fed an
      exclusive human milk diet during their initial hospitalization after birth and through the 30
      days post-surgical repair feeding period or hospital discharge, whichever comes first.

      Subjects will be randomized to one of two groups at birth or immediately following diagnosis
      if prenatal care was not obtained prior to birth. Parents who decline participation by their
      infants in the study will be asked to consent to data gathering on their infants who will be
      treated and fed per institutional practice. The data on these individuals will be summarized
      and evaluated descriptively in comparison with the actual trial results.

      All patients will receive exclusive maternal human milk or donor human milk prior to
      randomization. Once randomized, patients in Group One will receive an exclusive human milk
      diet prior to the surgery and throughout the 30-day feeding period following surgical repair
      or until hospital discharge, whichever comes first. Day 1 is defined as the day of the first
      enteral feed post-surgery. Patients in Group Two (Control Group) will receive maternal human
      milk or formula or donor human milk (per standard of care at each hospital) in the
      pre-surgical period. In the post-surgical period the control group will receive human milk or
      formula, as per feeding algorithm The primary objective of this study is to evaluate growth
      velocity (weight velocity [g/kg/day] and weight z-score from World Health Organization (WHO)
      growth charts) at 30 days after the initiation of feed post-surgery for infants with single
      ventricle physiology who are fed an exclusive human milk diet from birth through the 30 day
      feeding period following surgical repair or until hospital discharge, whichever comes first.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>growth velocity</measure>
    <time_frame>30 days</time_frame>
    <description>weight velocity in g/kg/day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>growth velocity</measure>
    <time_frame>30 days</time_frame>
    <description>weight z-score 30 days post 1st operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>linear growth rate</measure>
    <time_frame>6 months</time_frame>
    <description>cm/week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>linear growth rate</measure>
    <time_frame>6 months</time_frame>
    <description>z-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>head circumference growth rate</measure>
    <time_frame>6 months</time_frame>
    <description>cm/week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>head circumference growth rate</measure>
    <time_frame>6 months</time_frame>
    <description>z-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feeding Intolerance</measure>
    <time_frame>30 days</time_frame>
    <description>defined as nil per os (NPO) for at least 24 in the 30 days of post-surgery enteral feeding period (day 1 is the first day of feeding post-op), NPO due to elective surgeries or procedures will not be defined as feeding intolerance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>up to 24 months</time_frame>
    <description>time hospitalized after 1st surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis</measure>
    <time_frame>30 days</time_frame>
    <description>Sepsis 30 days post 1st operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis</measure>
    <time_frame>30 days</time_frame>
    <description>NEC 30 days post 1st operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wound infections</measure>
    <time_frame>30 days</time_frame>
    <description>wound infection 30 days post 1st operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wound dehiscence</measure>
    <time_frame>30 days</time_frame>
    <description>wound dehiscence 30 days post 1st operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parenteral nutrition</measure>
    <time_frame>30 days</time_frame>
    <description>in days, during the 30 day post 1st operation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Congenital Heart Defect</condition>
  <arm_group>
    <arm_group_label>Exclusive Human Milk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All infants randomized to this arm will receive exclusive human milk diet with addition of human milk derived fortifier from birth to 30 days post initiation of feedings after initial palliative cardiac surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human/Bovine Milk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All infants randomized to this arm will receive exclusive human milk diet prior to randomization and will use either human and/or bovine milk and fortifier per the institution's standard practice 30 days post initiation of feedings after initial palliative cardiac surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Human Milk Derived Fortifier</intervention_name>
    <description>Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm</description>
    <arm_group_label>Exclusive Human Milk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Human/Bovine Milk</intervention_name>
    <description>Bovine milk derived fortification</description>
    <arm_group_label>Human/Bovine Milk</arm_group_label>
    <other_name>Human/Formula Milk</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Term infants (â‰¥37 and 0/7 weeks gestational age) â‰¤ 7 days old with a diagnosis of
             single ventricle physiology who are thought to require a single ventricle repair at
             the time of enrollment.

          2. Infant feeding was NPO or consisted of 100% human milk diet prior to enrollment

          3. Parent(s) willing to sign informed consent.

          4. Parent(s) willing to comply with study follow-up procedures.

          5. Require surgical palliation within the first 1 month of life.

        Exclusion Criteria:

          1. Term infants &gt;7 days old at the time of diagnosis.

          2. &lt;37 weeks gestation

          3. Infants requiring cardio-pulmonary resuscitation prior to surgical repair.

          4. Outborn infants who received enteral nutrition at the other institution prior to
             surgical repair. If it is uncertain if infant received even 1 bottle or a small amount
             of formula, infants will be excluded.

          5. Major congenital abnormalities that could significantly affect survival such as:

               1. Confirmed or suspected major genetic abnormalities (lethal or with extremely low
                  probability for survival).

               2. Chromosomal abnormalities: Trisomies (13, 18, 21 etc.) deletions or
                  translocations (Turner/Williams Syndrome, DiGeorge, to name a few)

               3. Major organ system abnormalities not related to a genetic syndrome that are
                  lethal or have extremely low probability for survival (i.e, bilateral kidney
                  intrinsic disease, pulmonary hypoplasia, Central Nervous System (CNS)
                  malformations: Arnold Chiari, myelomeningoceles, hydranencephaly, schizencephaly,
                  holoprosencephaly))

               4. Heterotaxia

               5. Metabolic disorders affecting growth: homocystinuria, methylmalonic acidemias,
                  propionic acidemias, urea cycle defects

          6. Evidence of intracerebral hemorrhage (IVH) â‰¥ Grade 3

          7. Any comorbidity or significant clinical event prior to enrollment, deemed by the
             Investigator as likely to affect survival.

          8. Requires Extracorporeal Membrane Oxygenation (ECMO) pre-operatively

          9. Legally Authorized Representative(s) unwilling to comply with an exclusive human milk
             diet either in the form of mother's milk, human milk-based human milk fortifier, human
             milk based caloric fortifier or donor human milk during the initial hospitalization
             period and through the 30 day feeding period after surgical repair or hospital
             discharge, whichever comes first.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Blanco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Piacentino, BScN CRAII</last_name>
    <phone>310-748-7237</phone>
    <email>APiacentino@prolacta.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Tragus, RN</last_name>
    <phone>210-567-5262</phone>
    <email>tragus@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitch Goldstein, MD</last_name>
      <phone>909-558-7448</phone>
      <email>Mgoldstein@Iiu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lila Dalton</last_name>
      <email>Ldalton@Iiu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Los Angeles Children's Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheryl Takao, MD</last_name>
      <phone>323-361-1871</phone>
      <email>Ctakao@chla.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jay Pruetz, MD</last_name>
      <email>Jpruetz@chla.usc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Ashrafi, MD</last_name>
      <phone>714-509-4373</phone>
      <email>amir.asrafi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Steele</last_name>
      <phone>714-509-3023</phone>
      <email>CSteele@choc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Florida Children's Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Cacho, MD</last_name>
      <email>nicole.cacho@peds.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Desiree Machado, MD</last_name>
      <phone>352-273-7770</phone>
      <email>desireemachado@ufl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Marino, MD</last_name>
      <phone>800-543-7362</phone>
      <email>bradley.marino@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Van't Hof</last_name>
      <phone>312-227-1549</phone>
      <email>kvanthof@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bradley Marino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudha Kashyap, MD</last_name>
      <phone>212-305-9034</phone>
      <email>sk48@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marianne Garland, MB</last_name>
      <phone>212-305-0954</phone>
      <email>mg71@columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sudha Kashyap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinatti Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Allaben, MS</last_name>
      <phone>513-803-2995</phone>
      <email>Bryan.Allaben@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Faust</last_name>
      <phone>513-803-0349</phone>
      <email>michelle.faust@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsey Justice, NP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OU Children's Hospital at OU Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Williams, MD</last_name>
      <phone>405-271-5215</phone>
      <phone_ext>41571</phone_ext>
      <email>patricia-k-williams@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mike McCoy, MS</last_name>
      <email>mike-mccoy@ouhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joshua Wolovits, MD</last_name>
      <email>joshua.wolovits@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erin Gordon, MD</last_name>
      <phone>214-456-1811</phone>
      <email>erin.gordon@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Erin Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelli Brazzel, RN</last_name>
      <phone>682-885-6837</phone>
      <email>kelli.brazzel@cookchildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Beth Camacho, MSN</last_name>
      <phone>682-885-3395</phone>
      <email>beth.camacho@cookchildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heejy Yang</last_name>
      <phone>832-826-7991</phone>
      <email>jpunger1@texaschildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Amy Hair, MD</last_name>
      <phone>832-826-3719</phone>
      <email>abhair@texaschildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Hair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Tragus, RN</last_name>
      <phone>210-567-5262</phone>
      <email>tragus@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laurie Weaver, RN</last_name>
      <phone>2108872868</phone>
      <email>laurie.weaver@uhs-sa.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cynthia L Blanco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>October 21, 2019</last_update_submitted>
  <last_update_submitted_qc>October 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single Ventricle</keyword>
  <keyword>Congenital Heart Defect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is a blinded study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

